New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis
Key Highlights
- ➤EBGLYSS (LLY) achieved clear or almost clear hands and feet in 53% at Week 16
- ➤Week 16 skin clearance reached 53% with EBGLYSS versus 27% for placebo
- ➤Hand and foot itch improvement reached 57% with EBGLYSS versus 19% placebo
- ➤Hand and foot pain improvement reached 59% with EBGLYSS versus 19% placebo
- ➤Lilly (LLY) submitted ADtouch data to FDA for potential label update
Expert Statements
Mark Genovese, Senior Vice President of Lilly Immunology Development
“Data from the ADtouch study provide further evidence that EBGLYSS has the potential to rapidly improve skin clearance and itch and provide pain relief in the hands and feet without the need for topical treatments, giving people with moderate-to-severe atopic dermatitis the opportunity to spend less time managing symptoms.”
Shawn G. Kwatra, Joseph W. Burnett Endowed Professor and Chair in Dermatology, Chief of Service, Dermatology, University of Maryland School of Medicine and University of Maryland Medical Center
“Patients treated with lebrikizumab experienced significant improvements in pain and itch, with nearly three times as many patients achieving meaningful pain improvement compared with placebo.”
New Phase 3b data show Lilly's EBGLYSS (lebrikizumab-lbkz) delivered significant and rapid improvements in skin clearance, itch, pain, and patient satisfaction in people with moderate-to-severe hand and foot atopic dermatitis PR Newswire
EBGLYSS monotherapy met its primary endpoint with more than half of patients achieving clear or almost clear skin on their hands and feet (HF-IGA 0/1) by Week 16, with significant skin clearance as early as one month
Get started
Create a free account to read the full story.